These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30831104)

  • 21. Bleeding patterns with the 19.5 mg LNG-IUS, with special focus on the first year of use: implications for counselling.
    Beckert V; Ahlers C; Frenz AK; Gerlinger C; Bannemerschult R; Lukkari-Lax E
    Eur J Contracept Reprod Health Care; 2019 Aug; 24(4):251-259. PubMed ID: 31223042
    [No Abstract]   [Full Text] [Related]  

  • 22. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study.
    Gemzell-Danielsson K; Inki P; Boubli L; O'Flynn M; Kunz M; Heikinheimo O
    Hum Reprod; 2010 Feb; 25(2):354-9. PubMed ID: 19955104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding changes after levonorgestrel 52-mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding.
    Chen BA; Eisenberg DL; Schreiber CA; Turok DK; Olariu AI; Creinin MD
    Am J Obstet Gynecol; 2020 Apr; 222(4S):S888.e1-S888.e6. PubMed ID: 31866516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems.
    Goldthwaite LM; Creinin MD
    Contraception; 2019 Aug; 100(2):128-131. PubMed ID: 31051118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of low-dose levonorgestrel-releasing intrauterine system in Chinese women: a multicenter, single-arm, open labeled interventional trial].
    Qian CF; Fan GS; Liao QP; Wu SY; La DD; Di W; Dong BH; Liu HW; Tang LD; Xiong ZA; Zhang HW; Hu YL; Yang NM; Ren ML; Shi H; Deng GP; Huang ZR
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):409-413. PubMed ID: 29961284
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F; Dilbaz B; Karadag B; Deveci CD
    J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
    Wildemeersch D; Goldstuck ND; Jackers G
    Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby AE; Cooke I; Rees M
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the use of two new low-dose levonorgestrel-releasing intrauterine systems as contraceptives.
    Bahamondes L; Bahamondes MV
    Womens Health (Lond); 2012 May; 8(3):235-8. PubMed ID: 22554171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a combined indomethacin and levonorgestrel-releasing intrauterine system on short-term postplacement bleeding profile: a randomized proof-of-concept trial.
    Fels LM; Costescu D; Vieira CS; Peipert JF; Lukkari-Lax E; Hofmann BM; Reinecke I; Klein S; Wiesinger K; Lindenthal B; Speer R
    Am J Obstet Gynecol; 2023 Mar; 228(3):322.e1-322.e15. PubMed ID: 36424684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expulsions and adverse events following immediate and later insertion of a levonorgestrel-releasing intrauterine system after medical termination of late first- and second-trimester pregnancy: a randomised controlled trial.
    Korjamo R; Mentula M; Heikinheimo O
    BJOG; 2017 Dec; 124(13):1965-1972. PubMed ID: 28692170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen.
    Weisberg E; Merki-Feld GS; McGeechan K; Fraser IS
    Contraception; 2015 Feb; 91(2):121-6. PubMed ID: 25459098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of action of the levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding.
    Cihangir U; Ebru A; Murat E; Levent Y
    Int J Gynaecol Obstet; 2013 Nov; 123(2):146-9. PubMed ID: 24028852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg.
    Teunissen AM; Merry AHH; Devies IEC; Roumen FJME
    Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):449-456. PubMed ID: 31696740
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.